Search results
Showing 211 to 225 of 272 results for carcinoma
We have moved interventional procedures guidance 2 to become HealthTech guidance 1. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS17Show all sections
Sections for QS17
Discontinued Reference number: GID-TA11005
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Photodynamic therapy for advanced bronchial carcinoma (IPG87)
We have moved interventional procedures guidance 87 to become HealthTech guidance 54. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)
This guidance has been replaced by NICE technology appraisal guidance 474.
Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)
This guidance has been updated and replaced by NICE technology appraisal guidance 555.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
High dose rate brachytherapy for carcinoma of the cervix (IPG160)
We have moved interventional procedures guidance 160 to become HealthTech guidance 104. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.